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creativecommons.org/licenses/by-nc-nd/Abstract Background: Mucositis and dysphagia are common adverse effects of radiotherapy
(RT) treatment of locally advanced squamous cell cancer of the head and neck (LA-SCCHN).
Chemotherapy added to RT increases survival rates but causes worse mucositis and
dysphagia. The aim of this analysis was to assess the impact of p16 status on mucositis,
dysphagia, and feeding tube use in LA-SCCHN among patients treated with RT cetuximab
in the phase 3 IMCL-9815 trial.
Methods: Patients received RT plus weekly cetuximab or RT alone. Subgroup analyses were
conducted on patients with p16-positive (nZ 75) or p16-negative (nZ 106) oropharyngeal
cancer (OPC), as determined by immunohistochemical analysis. The onset and duration of34 7185.
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08
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
J.A. Bonner et al. / European Journal of Cancer 64 (2016) 1e112mucositis and dysphagia by treatment arm and p16 status were displayed using KaplaneMeier
curves and the log-rank test. P values for the incidence of mucositis and dysphagia were calcu-
lated using the Fisher exact test. Feeding tube use was assessed as the percent of patients re-
porting use.
Results: The baseline characteristics of patients treated with RT cetuximab were similar in
both the p16-positive and p16-negative OPC subgroups. Patients within the p16-positive
OPC subgroup had higher Karnofsky scores and were more likely to have stage T1eT3 cancer
and be from the United States. Regardless of p16 status, there was no difference in the onset or
duration of grade 3/4 mucositis or dysphagia in patients receiving RT plus cetuximab
compared with those receiving RT alone. In the overall population, and the p16-positive
and p16-negative OPC subpopulations, feeding tube use was not different for patients
receiving RT plus cetuximab compared with RT alone.
Conclusion: Regardless of p16 status, the addition of cetuximab to RT did not alter the inci-
dence, time to onset, severity, or duration of mucositis and dysphagia and did not impact the
frequency of feeding tube use.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Radiotherapy (RT) for locally advanced head and neck
squamous cell carcinoma (LA-SCCHN) can induce
mucositis, pain, dysphagia, and diminished quality of
life [1,2]. Severe mucositis contributes to the need for
narcotic analgesics, intravenous fluids, and gastrostomy
feeding and may lead to unplanned RT interruptions,
thereby compromising outcomes [3,4]. Concurrent
chemotherapy improves survival rates for patients with
SCCHN compared with RT alone, but often at the
expense of increased mucositis and dysphagia. In
contrast, the phase 3 IMCL-9815 trial, which investi-
gated addition of the antieepidermal growth factor re-
ceptor (EGFR) monoclonal antibody cetuximab to RT,
showed that cetuximab did not appear to worsen these
toxicities when added to RT.
These findings and the recent availability of p16 an-
alyses of the IMCL-9815 study prompted us to re-
evaluate these toxicities by characterizing onset, dura-
tion, and incidence in both p16-positive and p16-
negative oropharyngeal cancer (OPC). Analysis of the
IMCL-9815 trial recently showed that patients with
either p16-positive or p16-negative OPC benefitted from
the addition of cetuximab to RT [5]. An interaction
analysis did not indicate that there was an association
between p16 status and the efficacy of cetuximab [5]. We
believe that it is important to further examine the
toxicity profiles of the p16-positive and p16-negative
groups. Our rationale for this belief is further under-
scored by the vast differences in prognosis between p16-
positive and p16-negative OPC: for patients with p16-
positive disease, their long life expectancy highlights
the need for efficacious therapies that incur fewer long-
term adverse effects (e.g. feeding tube use); in contrast,for patients with poorer-prognosis p16-negative disease,
their increased fragility necessitates the avoidance of
potentially severe adverse effects (e.g. mucositis).
This study is the first to examine the rate of onset and
duration of radiation-induced mucositis and dysphagia
for patients receiving RT alone or RT and cetuximab. In
addition, the role of p16 status was evaluated in the
incidence, onset, and duration of mucositis and
dysphagia, as well as feeding tube use, in patients with
OPC receiving RT plus cetuximab compared with those
receiving RT alone in the IMCL-9815 trial.2. Methods
2.1. Study design
The design of the phase 3, randomized IMCL-9815
cetuximab registration trial has previously been reported
in detail [6,7]. Patients with LA-SCCHN were ran-
domized to receive cetuximab plus RT once daily
(2.0 Gy/fraction; 5 fractions/week for 7 weeks), twice
daily (1.2 Gy/fraction; 10 fractions/week for 6.0e6.5
weeks), or concomitant boost (72 Gy in 6 weeks, using
twice-daily fractionation for the final 2.4 weeks) or RT
alone. The trial protocol was approved by the ethics
committees of all participating centres. The primary
end-point of the study was the duration of locoregional
control. Secondary end-points included overall survival,
progression-free survival, and response rate. Quality of
life and incidence of adverse events were also evaluated.
In this retrospective subgroup analysis, feeding tube use
and the incidence of mucositis and dysphagia were
evaluated in the overall safety population (nZ 181), as
well as subpopulations of patients with p16-positive and
Intent-to-treat population
(n = 424)
p16− OPC
(n = 106)
p16+ OPC
(n = 75)
RT + cetuximab
(n = 43)
RT alone
(n = 63)
RT alone
(n = 34)
RT + cetuximab
(n = 41)
p16-evaluable OPC
(n = 181)
Excluded (n = 239)
due to non-OPC or 
p16 non-evaluable
OPC status
Safety population
(n = 420)
Fig. 1. Selection of patients for p16 subgroup analysis. OPC, oropharyngeal carcinoma; RT, radiotherapy.
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discussion), for evaluation of the onset and duration of
mucositis and dysphagia, only those patients in the
overall safety population who received at least one dose
of RT were included (nZ 180).
2.2. Safety assessment
Toxicity was assessed using the Radiation Therapy
Oncology Group (RTOG) criteria [8]. Assessments of
acute toxicity were carried out during weekly RT and
through the eighth week after treatment. Late radiation
effects were assessed thereafter using RTOG toxicity
scales. Mucositis was defined as aphthous stomatitis,
gingivitis, glossitis, mouth ulceration, mucous mem-
brane disorder, stomatitis, or ulcerative stomatitis. The
onset of mucositis and dysphagia was calculated from
the date of the first RT until the first day of mucositis/
dysphagia. Duration was calculated from the day of the
first onset until resolution to grade 0 or end date.
Feeding tube use was derived from a subset of the Eu-
ropean Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire Head
and Neck Cancer (QLQeH&N35) questionnaire.
Scoring was carried out as defined by the EORTC
scoring manual. All scores were derived from mutually
exclusive sets of items, with scale scores ranging from
0 to 100 after a linear transformation. Data for feeding
tube use were reported as the percent of patients with a
feeding tube placed; in our study, feeding tubes were
inserted on a patient-needed basis (pre-emptive use was
not pre-specified in the protocol, nor was it forbidden).2.3. p16 Assessment
The effect of human papillomavirus (HPV) status on the
incidence, onset, and duration of mucositis and
dysphagia in patients with OPC was evaluated by
determining the presence of p16 as a surrogate marker
of HPV in the 181 evaluable patients that comprised the
safety population (Fig. 1). p16 Protein expression status
was evaluated by means of immunohistochemical anal-
ysis using the CINtec histology kit (Ventana Medical
Systems Inc, Tucson, AZ, USA). Positive p16 expression
was defined as strong and diffuse nuclear and cyto-
plasmic staining in 70% of the tumour cells [9].
2.4. Statistical analysis
The Fisher exact test was used to evaluate differences in
baseline characteristics between treatment arms and to
calculate P values for the incidence of mucositis and
dysphagia. The onset and duration of toxicities were
estimated using the KaplaneMeier method. Log-rank
tests were used to compare the time courses. When du-
rations of mucositis and dysphagia were evaluated, pa-
tients were censored if their end date was not available
or if their outcome was listed as ongoing.
3. Results
3.1. Baseline characteristics and study populations
The baseline characteristics of the patients in the intent-
to-treat population (nZ 424), the OPC population
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are presented in Table 1. Characteristics of the total
OPC and p16-evaluable OPC populations were similar.
Patients with p16-positive OPC had higher Karnofsky
scores and were more likely to have stage T1eT3 cancer
and be from the United States. Patients with p16-
positive OPC were more likely to have received
concomitant boost RT. Treatment arms were well
balanced with respect to RT regimen. Baseline charac-
teristics of patients receiving RT plus cetuximab or RT
alone were well balanced within the p16-positive
(nZ 75) and p16-negative (nZ 106) OPC subsets
(Table 1).
The majority of the findings presented in the current
analysis were derived from the safety data set; this in-
cludes analysis of the overall safety population and the
p16 subgroups (Fig. 1). Of the 420 patients in the safety
population, 208 were randomized to receive RT plus
cetuximab and 212 received RT alone (Table 2).3.2. Mucositis and dysphagia in the safety population
There was no difference in the incidence of all-grade or
grade 3/4 mucositis and dysphagia in patients treated
with RT plus cetuximab or RT alone (Table 2). Because
the treatment arms were well balanced with respect to
RT regimen, RT regimens were pooled to assess the
onset and duration of mucositis and dysphagia. There
was no difference in the onset or duration of grade 3/4
mucositis in patients receiving RT plus cetuximab or RT
alone (Fig. 2A and B). Similarly, the onset and duration
of grade 3/4 dysphagia were not significantly different in
patients who received RT plus cetuximab or RT aloneTable 1
Baseline characteristics of patients with OPC.
Parameter OPCa
All nZ 253
(%)
p16-Evaluable
nZ 182 (%)
Sex Male 81 79
Age <65 Years 77 75
Site of primary tumour Oropharynx 100 100
Karnofsky score >80 73 76
Nodal stage N0 11 13
Tumour stage T1eT3 72 71
EGFR expression: %
positive cells
50% 46 59
>50% 32 40
Unknown 22 1
Radiation fractionation Concomitant
boost
58 65
Once daily 23 21
Twice daily 17 13
Region United States 64 64
EGFR, epidermal growth factor receptor; OPC, oropharyngeal cancer; RT
a Demography analysis was performed on the intent-to-treat population
b The Fisher exact test did not reveal a significant difference between tre(Fig. 2C and D). These findings remained consistent
when all grades of mucositis and dysphagia were
considered (Supplementary Table 1). When all RT reg-
imens were considered, the addition of cetuximab did
not significantly impact the onset or duration of all-
grade or grade 3/4 mucositis and dysphagia
(Supplementary Tables 1 and 2).
In contrast, the type of RT regimen had an effect on
the incidence of mucositis and dysphagia. Patients who
received altered-fractionation RT experienced signifi-
cantly more events compared with patients who received
once-daily RT, regardless of whether cetuximab was
included in the regimen (Table 3). However, with the
exception of a significantly later onset of dysphagia in
patients who received twice-daily RT compared with
those who received twice-daily RT plus cetuximab, there
was no significant effect of the addition of cetuximab on
the onset or duration of all-grade or grade 3/4 mucositis
and dysphagia in patients receiving once-daily, twice-
daily, or concomitant boost RT regimens
(Supplementary Tables 1 and 2).3.3. p16 Subset analysis of mucositis and dysphagia
In the p16-positive and p16-negative OPC populations,
the incidence of all-grade and grade 3/4 mucositis and
dysphagia was not significantly different between treat-
ments arms (Table 2). Within the p16-positive popula-
tion, the addition of cetuximab showed a trend toward
more cases of grade 3/4 mucositis, all-grade dysphagia,
and grade 3/4 dysphagia compared with treatment with
RT alone. In the p16-negative population, there was a
trend toward more cases of grade 3/4 mucositis butp16-Positiveb p16-Negativeb
RTþ cetuximab
nZ 41 (%)
RT nZ 34
(%)
RTþ cetuximab
nZ 43 (%)
RT nZ 64
(%)
83 82 77 77
81 74 81 67
100 100 100 100
90 82 65 70
7 9 14 17
83 88 51 69
71 62 51 55
27 38 49 44
2 0 0 2
78 71 56 59
2 9 35 30
17 21 9 9
95 91 47 41
, radiotherapy.
.
atment arms.
Table 2
Incidence of adverse events by treatment arm in the overall safety population.
Adverse Event Grade Overall safety populationa,b OPCb
p16-Positive (n Z 74) p16-Negative (nZ 106)
RTþ cetuximab
nZ 208 (%)
RT nZ 212 (%) RTþ cetuximab
nZ 40 (%)
RT nZ 34 (%) RTþ cetuximab
nZ 43 (%)
RT nZ 63 (%)
Mucositis All grades 93 94 100 100 98 95
Grades 3e4 56 52 78 71 65 56
Dysphagia All grades 65 63 80 76 51 57
Grades 3e4 26 30 45 38 16 24
OPC, oropharyngeal cancer; RT, radiotherapy.
a Rates of mucositis and dysphagia within the overall safety population were previously published in the study by Bonner et al. [6].
b The Fisher exact test determined that there was no P< 0.05 when treatment arms were compared.
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cetuximab arm. These trends did not reach significance
(Table 2).
In those with p16-positive or p16-negative tumours,
the time to onset and duration of grade 3/4 mucositisFig. 2. KaplaneMeier estimates of onset and duration of grade 3/4 mu
and C) and duration (B and D) of grade 3/4 mucositis (A and B) a
definition, only those patients in the overall safety population who rece
combined. RT, radiotherapy.were not altered by the addition of cetuximab to RT
(Fig. 3). When all grades of mucositis were considered,
there was a nonsignificant trend toward a later onset of
mucositis in p16-negative patients who received RT
alone (Supplementary Table 3). The duration of allcositis and dysphagia in the applicable safety population. Onset (A
nd dysphagia (C and D) in the applicable safety population (by
ived at least one dose of RT were included). All RT regimens were
Table 3
Rates of mucositis and dysphagia in the overall safety population by RT regimen.
Adverse event Grade RTþ cetuximab RT
Once-daily
fractionation
(n Z 55) (%)
Altered fractionationa
(nZ 155) (%)
P valueb Once-daily
fractionation
(nZ 50) (%)
Altered fractionationa
(nZ 157) (%)
P valueb
Mucositis All grades 81.8 94.9 0.009 96 97.4 0.635
Grades 3e4 25.5 65 <0.001 22 63.8 <0.001
Dysphagia All grades 50.9 68.8 0.022 58 67.7 0.233
Grades 3e4 16.3 28.6 0.075 16 35.4 0.013
RT, radiotherapy.
a Twice daily or concomitant-boost RT.
b The Fisher exact test was used to determine the P value.
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received RT plus cetuximab appeared to be numerically
longer compared with that of patients who received RT
alone (Supplementary Table 3). Although notFig. 3. KaplaneMeier estimates of onset and duration of grade 3/4 m
and B) and duration (C and D) of grade 3/4 mucositis in the p16-po
definition, only those patients in the overall safety population who rece
combined. OPC, oropharyngeal cancer; RT, radiotherapy.significant, there was a numerical increase in the dura-
tion of all grades of dysphagia in patients with p16-
negative disease who received cetuximab plus RT
(Supplementary Table 3).ucositis in the applicable p16-evaluable OPC subgroups. Onset (A
sitive (A and C) and p16-negative (B and D) OPC subgroups (by
ived at least one dose of RT were included). All RT regimens were
Fig. 4. KaplaneMeier estimates of onset and duration of grade 3/4 dysphagia in the applicable p16-evaluable OPC subgroups. Onset (A
and B) and duration (C and D) of grade 3/4 dysphagia in the p16-positive (A and C) and p16-negative (B and D) OPC subgroups (by
definition, only those patients in the overall safety population who received at least one dose of RT were included). All RT regimens were
combined. OPC, oropharyngeal cancer; RT, radiotherapy.
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all-grade and grade 3/4 mucositis did not appear to be
different in patients with p16-positive tumours versus
those with p16-negative tumours (Table 2, Figs. 3 and 4,
and Supplementary Table 3). Patients with p16-positive
OPC had a numerically higher incidence of grade 3/4
mucositis and dysphagia compared with those with p16-
negative OPC (Table 2), and the onset of dysphagia in
patients with p16-negative OPC occurred later
compared with patients with p16-positive disease in both
treatment arms (Supplementary Table 3).
3.4. Feeding tube use
The use of feeding tubes as assessed by responses to the
EORTC QLQ-H&N35 questionnaire during and afterRT was evaluated in the overall population and the
p16-positive and p16-negative OPC subgroups. In the
overall population, there was no difference between
feeding tube use at 2 months after RT for patients
receiving RT plus cetuximab (nZ 175) compared with
RT alone (nZ 159) (Fig. 5). This remained consistent
12 months after RT. In both the p16-positive and the
p16-negative subgroups, the rate of placement of
feeding tubes at 2 and 12 months after RT was similar
for patients who received RT in combination with
cetuximab or RT alone (Fig. 5B and C). Compared
with patients with p16-positive OPC, the reported use
of feeding tubes at 12 months appeared to be numeri-
cally greater in patients with p16-negative OPC
(Fig. 5B and C).
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Although some investigations of single-institution ex-
periences have suggested that the addition of cetuximab
to RT may result in increased rates of grade 3 muco-
sitis, compared with radiation alone [10e12], this is the
only prospectively randomized trial of these treatments,
and these results demonstrated no treatment-related
differences in rates of this toxicity. In addition, this is
the first report showing that the addition of cetuximab
did not alter the rate of onset or duration of grade 3
mucositis or dysphagia. Our results have been supported
by other single-institution studies [13,14]. Other reviews
have suggested that mucosal toxicities occur less
frequently with cetuximab and RT treatment compared
with cisplatin and RT treatment [15]. The studies that
have suggested increased rates of mucositis for the
addition of cetuximab to RT have generally been small
studies (14e34 patients) and their processes for treat-
ment selection were not well defined. The finding that
the incidence, onset, and duration of grade 3 mucositis
and dysphagia were comparable for RT cetuximab is
important information for physicians who are selecting
treatments and consulting with patients regarding po-
tential side-effects. Furthermore, this study included a
retrospective analysis of HPV status and revealed that
rates of mucositis and dysphagia were not increased
with the addition of cetuximab to RT in either the HPV-
positive or HPV-negative population.
We found that for patients enrolled in the prospective
IMCL-9815 trial for LA-SCCHN, the addition of
cetuximab to RT did not alter the incidence, time to
onset, severity, or duration of mucositis and dysphagia,
specifically including grade 3 dysphagia defined as
requiring gastrostomy feeding tubes. We recently pub-
lished the efficacy analysis showing that both the p16-
positive and p16-negative subgroups had higher
locoregional control and overall survival with the
addition of cetuximab, although the difference is much
greater for the p16-positive group.
Patients in this study were treated with standard-
fractionation, altered-fractionation, concomitant boost,
or hyperfractionation RT. It is well known that altered-
fractionation RT can increase the severity of mucositis.
However, in both the standard- and altered-
fractionation groups, the severity of mucositis peaked
during the last week of treatment. At 12 weeks after the
start of treatment, fewer than 10% of patients in both
groups had grade 3/4 mucositis; by week 16, almost all
patients had healed. Most patients in our study received
concomitant boost RT. Although both altered-
fractionation RT regimens resulted in a slightly higherFig. 5. Feeding tube use in the overall safety population and p16-eva
feeding tube before, during, and 1 year after RT treatment in the ove
OPC subgroups (C). F/U, follow-up; OPC, oropharyngeal cancer; RTincidence of mucositis and dysphagia, the onset and
duration of these events did not appear to be affected by
RT regimen in the overall or the p16-evaluable OPC
populations.
In addition, it is important to note that this trial was
conducted in the era of three-dimensional conformal RT
and not the more current standard of intensity-
modulated radiotherapy (IMRT) for SCCHN. Studies
comparing three-dimensional conformal RT and IMRT
have shown that IMRT does not reduce the peak inci-
dence of mucositis but may decrease its volume and
allow for dose reduction to the pharyngeal constrictors
[16]. Therefore, the use of a systemic agent such as
cetuximab that does not appear to enhance radiation-
induced mucositis remains highly relevant in the
IMRT era.
In the overall safety population and p16-evaluable
subgroups, we found no significant difference in the rate
of feeding tube use during the first year after RT in
patients receiving RT plus cetuximab or RT alone.
However, there appeared to be a numerically greater
incidence of feeding tube usage in patients with p16-
negative disease at 12 months after RT. This may be due
to underlying differences in patient demographics,
including tumour status, performance status, and
United States/noneUnited States origin. Furthermore,
HPV-negative patients were more likely to have greater
tobacco exposure and more comorbidities than their
HPV-positive counterparts [17], which may have
contributed to the need for feeding tubes. Although no
background characteristics could be confirmed as pre-
dictors of feeding tube use in the present trial, this is an
interesting hypothesis that could be explored in larger,
ongoing studies. Indeed, a limitation of our study is the
relatively modest number of patients with feeding tube
information available beyond 8 weeks after RT and we
cannot exclude the possibility that this patient subgroup
is not representative of the entire study patient popula-
tion at risk; nevertheless, our data do not suggest a
difference in feeding tube use between treatment arms.
Given our prior finding that patients with p16-positive
or p16-negative OPC benefitted from the addition of
cetuximab to RT [5], the present study suggests that
cetuximab did not increase mucositis and dysphagia rates
in either of these populations. Some observed minor
differences in the incidence and kinetics of mucositis and
dysphagia in the p16-positive and p16-negative pop-
ulations may be attributable to the differences between
smoking-related and HPV-related disease. The data from
this study suggest that cetuximab does not increase acute
toxicities in HPV-positive patients while still benefiting
overall outcome. However, small sample size is aluable OPC populations. Frequency of patient-reported use of a
rall safety population (A) and p16-positive (B) and p16-negative
, radiotherapy.
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regarded as hypothesis generating.
Several ongoing and recently completed trials are
investigating the treatment of HPV-positive OPC with
RT and cetuximab. The RTOG recently enrolled 987
patients to RTOG 1016, a phase 3 randomized study to
compare the treatment of HPV-positive OPC with RT in
combination with either cisplatin or cetuximab [18]. The
results of this study, which examines treatment efficacy,
treatment-related toxicity, and quality of life, are eagerly
anticipated. The Eastern Cooperative Oncology Group
has completed a phase 2 study (ECOG 1308), in which
patients with HPV-positive OPC received three cycles of
induction chemotherapy (ICT) consisting of cisplatin,
paclitaxel, and cetuximab [19]. Patients who demon-
strated a complete response to ICT received a reduced
dose of RT with weekly cetuximab. Those who did not
achieve a complete response underwent standard RT
with weekly cetuximab. Early findings from this study
demonstrated a 2-year overall survival rate of 95% in
patients who received reduced-dose RT plus cetuximab,
which increased to 97% when only patients with fewer
than 10 pack-years of smoking were considered. This
study suggests that the combination of low-dose RT
with cetuximab following ICT may be a worthy alter-
native regimen for further study.
Cetuximab is a valuable addition to the SCCHN
treatment paradigm. Over the last decade, HPV status
has emerged as a significant factor in disease aetiology
and treatment outcome. The present study suggests that
regardless of p16 status, when added to RT, cetuximab
does not appear to increase the incidence, onset, or
duration of severe mucositis and dysphagia. Further-
more, the addition of cetuximab to RT does not appear
to increase the use of feeding tubes during the first year
after RT. Given the growing incidence of OPC affecting
younger, healthier patientsdwho have a high expected
cure ratedcompared with those with tobacco-driven
cancers, it is important to find the most effective ther-
apeutic regimen that produces the lowest rates of acute
mucositis and dysphagia because these acute toxicities
are associated with an increased risk for long-term
dysphagia, aspiration, and feeding tube requirement.
The results of this study support the use of cetuximab
for both p16-positive and p16-negative patients with
OPC. The maturing RTOG 1016 trial will give further
prospective comparison on the efficacy and toxicity
profile for cetuximab versus cisplatin for the p16-
positive population.Acknowledgements
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